1<!DOCTYPE html>
2
3Anonymous
4/bestp
5/bestp/domrep.nsf
61FA786A3B7F6F46465257917001F78B4
8
9
10
11
12
13
140
15
16
17/bestp/domrep.nsf/products/potential-pitfalls-for-oncology-product-launch-market-makeup-physicians-internal-issues?opendocument
18
19opendocument
2018.208.211.150
21
22
23www.best-in-class.com
24/bestp/domrep.nsf
25DB




Products & Services Product Launch Market Entry and Oncology

Pitfalls to Avoid for a Strong Oncology Market Entry: Current and Future Risk Levels for Product, Market, Physician, Patient, Payer, Internal and Regulatory Pitfalls

ID: 5159


Features:

15 Info Graphics

17 Data Graphics

100+ Metrics

4 Narratives


Pages/Slides: 38


Published: Pre-2013


Delivery Format: Online PDF Document


 

License Options:
close

Single User: Authorizes use by the person who places the order or for whom the order was placed.

Sitewide: Authorizes use of the report for a geographic site. All people at site can view the report for a year and copies can be printed.

Corporate: Authorizes use for the entire company for a year and copies can be printed. No limitations for usage inside the company.




Buy Now

 


  • STUDY OVERVIEW
  • BENCHMARK CLASS
  • SPECIAL OFFER
Non-members: Click here to review a complimentary excerpt from "Pitfalls to Avoid for a Strong Oncology Market Entry: Current and Future Risk Levels for Product, Market, Physician, Patient, Payer, Internal and Regulatory Pitfalls"

STUDY OVERVIEW

For a new oncology product to successfully enter the marketplace, organizations have to be vigilant of the many pitfalls that are part of the launch landscape. This research document highlights launch leaders' perspective on the current and future risk levels of potential pitfalls for critical oncology launch factors such as product and market makeup, physicians, patients, payers, internal issues and regulatory. Pharmaceutical product launch leaders can use this study to better understand the potential pitfalls and stumbling blocks that they'll have to navigate as part of a new oncology product entering the market.


KEY TOPICS

  • Pitfalls and Stumbling Blocks
  • Lessons Learned, Best Practices and Future Changes


SAMPLE METRICS
  • Estimate for the risk level of product shaping pitfalls that can derail a new oncology product coming into a crowded market
  • Estimate for the risk level of market shaping pitfalls that can derail a new oncology product coming into a crowded market
  • Estimate for the risk level of physician pitfalls that can derail a new oncology product coming into a crowded market
  • Estimate for the risk level of patient pitfalls that can derail a new oncology product coming into a crowded market
  • Estimate for the risk level of payer pitfalls that can derail a new oncology product coming into a crowded market
  • Estimate for the risk level of internal failure points that can derail a new oncology product coming into a crowded market
  • Estimate for the risk level of regulatory pitfalls that can derail a new oncology product coming into a crowded market


SAMPLE KEY FINDING
  • Physician-Level Pitfalls: Key Oncology stumbling blocks reside with thought leaders and critical specialists critics. However, health care access is seen as most likely risk to increase during the next two to three years.
  • Payer Risk Factors: Payer risk factors are in high alert across multiple therapeutic areas and across many fronts: Pricing, Priorities, Health Outcomes and Managed Markets. Looking ahead, over half of the Oncology participants see risk intensity continuing to rise.

METHODOLOGY

The research employed a data gathering approach that gleaned quantitative data from 44 executives and managers from 38 leading companies in pharmaceutical, biotechnology and medical device industries.


Industries Profiled:
Pharmaceutical; Biotech; Medical Device; Health Care; Chemical; Manufacturing; Consumer Products; Diagnostic; Media


Companies Profiled:
Abbott Laboratories; Amgen; Actelion; AstraZeneca; GlaxoSmithKline; Bristol-Myers Squibb; Roche; Lilly; Novartis; Merck; Genentech; MedImmune; Bayer; Cephalon; Inc.; Teva Neuroscience; Novo Nordisk; Amylin; Laboratorios Deramtologicos Darier; IDS Canada; UCB Pharma; Quintiles; Ther-Rx; ProCaps Laboratories; Baxter Healthcare; Synapse biomedical; Talecris; Eisai; Shire; Takeda Pharmaceuticals


If you purchase Best Practice Database document(s), you will have 30 days from the date of purchase to apply some or all of the cost of the document(s) toward the cost of a Full Access Individual, Pharma, Group or University Membership. Write us at DatabaseTeam@bestpracticesllc.com or call David Guinn at 919-767-9179 if you have any questions.